中牧股份(600195.SH)：蘭州廠涉及病原微生物的疫苗生產車間將於今年底前遷出蘭州廠現址
格隆匯1月14日丨中牧股份(600195.SH)公佈，公司於2019年12月27日披露了《中牧實業股份有限公司關於甘肅省衞生健康委員會網站通報事項的説明公告》。公司對事件進展情況説明如下：
2019年1月14日，甘肅省衞生健康委員會發布《甘肅省全力開展布魯氏菌抗體陽性事件處置工作》，就省市聯合調查組對蘭州廠調查進展情況進行了公佈，指出：“已於2019年12月7日關停了蘭州生物藥廠布魯氏菌疫苗生產車間，並於2020年1月13日撤銷了蘭州生物藥廠布病疫苗生產許可，同時已報請農業農村部儘快批覆撤銷蘭州生物藥廠布病疫苗產品批准文號。經與蘭州生物藥廠上級主管單位中牧集團溝通確認已啟動蘭州生物藥廠所有疫苗車間搬遷工作，在年內完成出城入園。目前，已協調其上級主管部門啟動問責追責工作”，“國家和省級疾控機構對蘭州廠周邊環境持續在進行抽樣檢測，未檢出布魯氏菌”。
在公司專項工作小組現場督導下，蘭州廠以布病疫苗車間為重點，對全廠執行《獸藥生產質量管理規範》已開展全面檢查，全力整改。公司安全生產委員會依據公司安全生產管理辦法、蘭州廠庫存物資管理制度等規定，已向蘭州廠作出書面決定，立即關閉獸用布病疫苗生產車間，並停止一切獸用布病疫苗生產活動。公司通過公司網站、公司的微信公眾號等渠道加大科普宣教力度，幫助員工科學認識布魯氏菌血清抗體陽性、布魯氏菌病，加強對員工生物安全防控知識的培訓，增強員工風險防範意識。
蘭州廠生產區整體搬遷項目於2018年11月22日經公司第七屆董事會2018年第八次臨時會議審議批准實施，目前廠房已經封頂，正在進行內部裝修和設備安裝。蘭州廠涉及病原微生物的疫苗生產車間將於2020年12月31日前遷出蘭州廠現址。
2018年，蘭州廠的布病疫苗生產車間實現營業收入918.34萬元，佔2018年公司營業收入的0.21%。2019年1月～9月，蘭州廠的布病疫苗生產車間實現營業收入865.64萬元，佔公司2019年前三季度營業收入的0.29%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
